{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:16:13Z","timestamp":1790727373875,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier","isbn-type":[{"value":"9780443192494","type":"print"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/bs.ircmb.2023.05.001","type":"book-chapter","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T21:04:39Z","timestamp":1686863079000},"page":"189-219","source":"Crossref","is-referenced-by-count":4,"title":["Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2023.05.001_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/rmv.1876","article-title":"Sindbis virus as a human pathogen-epidemiology, clinical picture and pathogenesis","volume":"26","author":"Adouchief","year":"2016","journal-title":"Reviews in Medical Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib2","doi-asserted-by":"crossref","first-page":"8413","DOI":"10.1128\/JVI.72.10.8413-8419.1998","article-title":"Effect of vesicular stomatitis virus matrix protein on transcription directed by host RNA polymerases I, II, and III","volume":"72","author":"Ahmed","year":"1998","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0609.2000.90147.x","article-title":"Stromal cells in lymph nodes attract B-lymphoma cells via production of stromal cell-derived factor-1","volume":"64","author":"Arai","year":"2000","journal-title":"European Journal of Haematology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06550.x","article-title":"Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma","volume":"137","author":"Au","year":"2007","journal-title":"British Journal of Haematology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib5","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1128\/jvi.66.7.4058-4064.1992","article-title":"Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo","volume":"66","author":"Black","year":"1992","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2013-09-528851","article-title":"Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity","volume":"123","author":"Castleton","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib7","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2015.88","article-title":"Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia","volume":"29","author":"Parrish","year":"2015","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K."},{"key":"10.1016\/bs.ircmb.2023.05.001_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.onc.1209055","article-title":"Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia","volume":"25","author":"Cesaire","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-021-00505-2","article-title":"Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia","author":"Cobaleda","year":"2021","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2021","journal-title":"Nature Reviews. Microbiology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib11","first-page":"3268","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"BLOOD Adv"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib12","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-11-0968","article-title":"Species D adenoviruses as oncolytics against B-cell cancers","volume":"17","author":"Chen","year":"2011","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib13","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","article-title":"Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter","volume":"103","author":"Dingli","year":"2004","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib14","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K."},{"key":"10.1016\/bs.ircmb.2023.05.001_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib16","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1158\/1078-0432.CCR-14-1404","article-title":"A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma","volume":"20","author":"Sborov","year":"2014","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib17","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1084\/jem.191.9.1487","article-title":"M11L: A novel mitochondria-localized protein of myxoma virus that blocks apoptosis of infected leukocytes","volume":"191","author":"Everett","year":"2000","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.molcel.2004.11.023","article-title":"VSV disrupts the Rae1\/mrnp41 mRNA nuclear export pathway","volume":"17","author":"Faria","year":"2005","journal-title":"Molecular Cell"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061383","article-title":"Talimogene Laherparepvec (T-VEC): An intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib20","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/gt.2010.103","article-title":"Mantle cell lymphoma salvage regimen: Synergy between a reprogrammed oncolytic virus and two chemotherapeutics","volume":"17","author":"Ungerechts","year":"2010","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/v13050718","article-title":"Coxsackievirus B3\u2014Its potential as an oncolytic virus","volume":"vol. 13","author":"Geisler","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-018-0442-1","article-title":"Nomenclature for endogenous retrovirus (ERV) loci","volume":"15","author":"Gifford","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib23","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood-2002-12-3817","article-title":"Leukemia in twins: Lessons in natural history","volume":"102","author":"Greaves","year":"2003","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-virology-092818-015550","article-title":"Adenovirus entry: From infection to immunity","volume":"6","author":"Greber","year":"2019","journal-title":"Annual Review of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib25","article-title":"Endogenous retroviruses in the human genome sequence","volume":"1","author":"Griffiths","year":"2001","journal-title":"Genome Biol. 2, reviews1017"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172991","article-title":"Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses","volume":"874","author":"Hadry\u015b","year":"2020","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib28","doi-asserted-by":"crossref","first-page":"12971","DOI":"10.18632\/oncotarget.24191","article-title":"CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma","volume":"9","author":"Hanauer","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41579-021-00665-x","article-title":"Diversity and evolution of the animal virome","volume":"20","author":"Harvey","year":"2022","journal-title":"Nature Reviews. Microbiology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib30","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1099\/vir.0.046672-0","article-title":"Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer","volume":"93","author":"Hastie","year":"2012","journal-title":"The Journal of General Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.769628","article-title":"Recent progress in interferon therapy for myeloid malignancies","volume":"vol. 11","author":"Healy","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib32","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1128\/JVI.01762-13","article-title":"Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes","volume":"87","author":"Hill","year":"2013","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/v13071406","article-title":"Targeting JAK\/STAT signaling antagonizes resistance to oncolytic reovirus therapy driven by prior infection with HTLV-1 in models of T-cell lymphoma","volume":"13","author":"Islam","year":"2021","journal-title":"Viruses-Basel"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib34","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10495-016-1276-8","article-title":"Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells","volume":"21","author":"Zhou","year":"2016","journal-title":"Apoptosis: An International Journal on Programmed Cell Death"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib36","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1038\/onc.2011.478","article-title":"Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma","volume":"31","author":"Kelly","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib37","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib38","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1038\/onc.2010.137","article-title":"The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status","volume":"29","author":"Kim","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2017.272","article-title":"Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy","volume":"32","author":"Kelly","year":"2018","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K."},{"key":"10.1016\/bs.ircmb.2023.05.001_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib41","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.1073\/pnas.95.20.11963","article-title":"Expression of the Epstein\u2013Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice","volume":"95","author":"Kulwichit","year":"1998","journal-title":"The Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.21444","article-title":"Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma","volume":"84","author":"Peng","year":"2009","journal-title":"American Journal of Hematology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/viro.2002.1479","article-title":"The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range","volume":"299","author":"Langland","year":"2002","journal-title":"Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00634-4","article-title":"CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma","volume":"12","author":"Lei","year":"2022","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib46","article-title":"Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma","volume":"125","author":"Lei","year":"2020","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/aps.2017.100","article-title":"Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro","volume":"39","author":"Li","year":"2018","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib48","doi-asserted-by":"crossref","unstructured":"Li, H. T. & Russell, S. J. (2013). Oncolytic Herpes Simplex Viruses Encoding an Antibody Retargeted C5a Complement Protein for Multiple Myeloma Therapy. Mol. Ther. 21, S156-S156. WE-Science Citation Index Expanded (SC).","DOI":"10.1016\/S1525-0016(16)34741-4"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/v13061082","article-title":"Development of group B coxsackievirus as an oncolytic virus: Opportunities and challenges","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib50","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/bloodadvances.2018025106","article-title":"p53 regulates CD46 expression and measles virus infection in myeloma cells","volume":"2","author":"Lok","year":"2018","journal-title":"Blood Advances"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001803","article-title":"Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche","volume":"9","author":"M\u00fcller","year":"2021","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib52","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-020-00919-w","article-title":"Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy","volume":"13","author":"Marchica","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2008","article-title":"Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses","volume":"28","author":"Matveeva","year":"2018","journal-title":"Reviews in Medical Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib55","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"The Iowa Orthopaedic Journal"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib56","first-page":"26","article-title":"Enhanced safety and efficacy of oncolytic VSV therapy by combination with T cell receptor transgenic T cells as carriers","volume":"12","author":"Melzer","year":"2019","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0092-8674(90)90374-N","article-title":"Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon","volume":"62","author":"Meurs","year":"1990","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-2011-3","article-title":"First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells","volume":"17","author":"Minev","year":"2019","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib59","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/infdis\/jiz318","article-title":"High-throughput sequencing-based investigation of viruses in human cancers by multienrichment approach","volume":"220","author":"Mollerup","year":"2019","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib60","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1158\/1078-0432.CCR-09-0451","article-title":"Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene","volume":"15","author":"Fernandes","year":"2009","journal-title":"Clinical Cancer Research: an Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib61","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.3390\/v6124999","article-title":"Interferon induction by RNA viruses and antagonism by viral pathogens","volume":"6","author":"Nan","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib62","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: from origins to outcomes","volume":"130","author":"Nangalia","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib63","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3324\/haematol.2013.087205","article-title":"Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD\/SCID mice","volume":"99","author":"L\u00fchl","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib64","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1172\/JCI9871","article-title":"Reovirus as a novel oncolytic agent","volume":"105","author":"Norman","year":"2000","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib65","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1128\/JVI.02601-07","article-title":"Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation","volume":"82","author":"Oliere","year":"2008","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib66","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K."},{"key":"10.1016\/bs.ircmb.2023.05.001_bib67","series-title":"Chapter 28 - Introduction to DNA viruses","first-page":"231","author":"Payne","year":"2017"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib68","series-title":"Chapter 36 - Family retroviridae","first-page":"287","author":"Payne","year":"2017"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib69","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1182\/blood-2002-07-2195","article-title":"Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker","volume":"101","author":"Peng","year":"2003","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib70","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ymthe.2020.09.041","article-title":"Oncolytic virus therapy with HSV-1 for hematological malignancies","volume":"29","author":"Ishino","year":"2021","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib71","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cytogfr.2010.02.010","article-title":"Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus","volume":"21","author":"Rahman","year":"2010","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib72","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5045\/kjh.2011.46.4.229","article-title":"Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions","volume":"46","author":"Raus","year":"2011","journal-title":"Korean J. Hematology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib73","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Current Opinion in Biotechnology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib75","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.celrep.2014.08.042","article-title":"SDF-1 inhibition targets the bone marrow niche for cancer therapy","volume":"9","author":"Roccaro","year":"2014","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib76","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2016.07.004","article-title":"Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery","volume":"237","author":"Rojas","year":"2016","journal-title":"The Journal of Controlled Release: the official journal of the Controlled Release Society"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib77","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/cgt.2012.14","article-title":"Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-\u03b2","volume":"19","author":"Naik","year":"2012","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib78","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/mt.2013.91","article-title":"BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis","volume":"21","author":"Samuel","year":"2013","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib79","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3892\/or.2021.7942","article-title":"Beclin1\u2013armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R\u2011CHOP against lymphoma in vitro and in vivo","volume":"45","author":"Xie","year":"2021","journal-title":"Oncology Reports"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.86","article-title":"Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma","volume":"vol. 5","author":"Saito","year":"2015","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib81","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002086","article-title":"Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy","volume":"9","author":"Shin","year":"2021","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib83","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clinic Proceedings. Mayo Clinic"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2019.103957","article-title":"Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy","volume":"140","author":"Sobhanimonfared","year":"2020","journal-title":"Microbial Pathogenesis"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib85","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1297-9716-42-76","article-title":"The current status and future directions of myxoma virus, a master in immune evasion","volume":"42","author":"Spiesschaert","year":"2011","journal-title":"Veterinary Research"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib86","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1517\/14712598.7.9.1415","article-title":"Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer","volume":"7","author":"Stanford","year":"2007","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02469","article-title":"Regulation of the germinal center response","volume":"9","author":"Stebegg","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib88","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","article-title":"The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus","volume":"17","author":"Strong","year":"1998","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.09.282","article-title":"Combination of herpes-simplex based oncolytic viruses (HSV-OV) with natural killer (NK) cells in Multiple Myeloma","volume":"19","author":"Susek","year":"2019","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib90","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/cas.12324","article-title":"Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150\/signaling lymphocytic activation molecule","volume":"105","author":"Takeda","year":"2014","journal-title":"Cancer Science"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib91","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semcancer.2010.07.001","article-title":"Can inhibition of the SDF-1\/CXCR4 axis eradicate acute leukemia? Semin","volume":"20","author":"Tavor","year":"2010","journal-title":"Cancer Biology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib92","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428190009148403","article-title":"CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells","volume":"36","author":"Tong","year":"2000","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib93","doi-asserted-by":"crossref","first-page":"860","DOI":"10.18632\/oncotarget.1018","article-title":"Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia","volume":"4","author":"Tong","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib94","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3892\/or.2014.3020","article-title":"PI3K inhibitor LY294002 inhibits activation of the Akt\/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus","volume":"31","author":"Tong","year":"2014","journal-title":"Oncology Reports"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib95","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1038\/sj.jid.5700529","article-title":"Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo","volume":"126","author":"K\u00fcnzi","year":"2006","journal-title":"The Journal of Investigative Dermatology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib96","article-title":"Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduction and Targeted Therapy."},{"key":"10.1016\/bs.ircmb.2023.05.001_bib97","doi-asserted-by":"crossref","first-page":"109973","DOI":"10.18632\/oncotarget.22409","article-title":"Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition","volume":"8","author":"Weisberg","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107437","article-title":"Mesenchymal stem cell carriers enhance antitumor efficacy induced by oncolytic reovirus in acute myeloid leukemia","volume":"94","author":"Wang","year":"2021","journal-title":"International Immunopharmacology"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib99","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/gt.2010.150","article-title":"CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy","volume":"18","author":"Yaiw","year":"2011","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib100","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0664-3","article-title":"Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody","volume":"7","author":"Yu","year":"2019","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2023.05.001_bib101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/ijlh.12454","article-title":"Expression analysis of BECN1 in acute myeloid leukemia: association with distinct cytogenetic and molecular abnormalities","volume":"38","author":"Zare-Abdollahi","year":"2016","journal-title":"International Journal of Laboratory Hematology"}],"container-title":["International Review of Cell and Molecular Biology","Viral Vectors in Cancer Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823000631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644823000631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T15:33:28Z","timestamp":1753457608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644823000631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780443192494"],"references-count":101,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2023.05.001","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}